Oryzon Genomics - Q3 results recap key upcoming inflection points
Oryzon has reported its Q324 results, the highlight of which was the borderline personality disorder (BPD) programme, with the final Phase IIb...
141 Views
Oryzon Genomics - FDA aligns on Phase III BPD plans
Oryzon Genomics has confirmed the FDA’s alignment with its proposed Phase III programme for vafidemstat in borderline personality disorder (BPD)....
261 Views
Oryzon Genomics - Final PORTICO data reaffirms potential in BPD
Oryzon has presented the results of the final analysis from the Phase IIb PORTICO trial, which evaluated the efficacy and safety of vafidemstat in...
180 Views
Oryzon Genomics - First patient dosed in new AML combination study
Oryzon Genomics has announced the commencement of patient dosing in the investigator-initiated Phase Ib trial evaluating iadademstat as a...
265 Views
Oryzon Genomics - Multiple milestones anticipated in H224
Oryzon’s Q224 results summarised an active quarter for its clinical pipeline, with multiple milestones expected in H224. Central to the H224...
157 Views